← Human Trials & Peer-Reviewed Studies
[Investigation of amylin level changes among obese patients at different glucose metabolic states and effects of rosiglitazone intervention]
Plain-language guide to PMID 22178829 (2011): randomized controlled trial of Amylin (Islet Amyloid Polypeptide) in 2 patients.
Key Facts
- PMID
- 22178829
- Journal
- Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Yuan GH et al. (4 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.
To measure the changes in plasma amylin level among obese patients at different glucose metabolic states, and to evaluate effects of rosiglitazone intervention on obese type 2 diabetes patients.
Who Took Part
According to the abstract, 2 patients were involved.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
A total of 92 obese patients were categorized into normal glucose tolerance group (Group A, n=31), impaired glucose tolerance group (Group B, n=30), and type 2 diabetes group (Group C, n=31) according to oral glucose tolerance test (OGTT) results.
Body mass index (BMI) and waist circumference of all the patients were measured, and their plasma amylin and true insulin levels measured by radioimmunoassay and EIA.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.
What Was Measured
Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Glucose, Glucose Tolerance Test, Hypoglycemic Agents, Islet Amyloid Polypeptide, Islets of Langerhans and Obesity.
What This Means in Plain Language
The paper is a randomized study of Amylin (Islet Amyloid Polypeptide) in 2 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2011 (Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences), a journal based in China.
More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.
Our Notes on the Compound
Amylin (Islet Amyloid Polypeptide): A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.